WallStSmart

DaVita HealthCare Partners Inc (DVA)vsThe Ensign Group Inc (ENSG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 155% more annual revenue ($14.01B vs $5.49B). ENSG leads profitability with a 6.9% profit margin vs 6.0%. DVA appears more attractively valued with a PEG of 0.45. DVA earns a higher WallStSmart Score of 70/100 (B).

DVA

Strong Buy

70

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 7.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22

ENSG

Buy

61

out of 100

Grade: C+

Growth: 8.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.15
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVAOvervalued (-12.9%)

Margin of Safety

-12.9%

Fair Value

$127.80

Current Price

$183.86

$56.06 premium

UndervaluedFair: $127.80Overvalued
ENSGSignificantly Overvalued (-39.8%)

Margin of Safety

-39.8%

Fair Value

$151.57

Current Price

$173.91

$22.34 premium

UndervaluedFair: $151.57Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA5 strengths · Avg: 9.6/10
PEG RatioValuation
0.4510/10

Growing faster than its price suggests

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

EPS GrowthGrowth
55.8%10/10

Earnings expanding 55.8% YoY

Debt/EquityHealth
-14.0910/10

Conservative balance sheet, low leverage

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
17.3%8/10

17.3% revenue growth

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
6.0%3/10

6.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

ENSG2 concerns · Avg: 3.5/10
P/E RatioValuation
26.7x4/10

Moderate valuation

Profit MarginProfitability
6.9%3/10

6.9% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on PEG Ratio, Return on Equity, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 17.3% demonstrates continued momentum. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : ENSG

The primary concerns for ENSG are P/E Ratio, Profit Margin.

Key Dynamics to Monitor

DVA profiles as a value stock while ENSG is a growth play — different risk/reward profiles.

DVA carries more volatility with a beta of 0.83 — expect wider price swings.

ENSG is growing revenue faster at 17.3% — sustainability is the question.

DVA generates stronger free cash flow (320M), providing more financial flexibility.

Bottom Line

DVA scores higher overall (70/100 vs 61/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Want to dig deeper into these stocks?